Cadrenal Therapeutics, Inc.
$2.00 -$0.04 (-1.96%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 23
From its Feb 25 high, the share price fell 76%.
Peak close $8.63 on Feb 25; trough close $2.03 on Jul 23. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -76% -
Jul 21
A material event was filed (Form 8-K).
8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 17
A material event was filed (Form 8-K).
8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Apr 30
The stock moved +19.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 30 -
Mar 31
The stock moved +20.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 31
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.